摘要
子宫内膜异位症是一种雌激素依赖性的妇科慢性炎症性疾病,在育龄妇女中的发病率为5%~10%,在子宫内膜异位症患者中有5%~50%表现为慢性盆腔疼痛,此外还有33%表现为不孕。第三代芳香化酶抑制剂(aromatase inhibitors,AIs)目前获批用于雌激素受体阳性的乳腺癌的治疗。分子生物学研究表明,芳香化酶P450是卵巢雌激素生物合成中的关键酶,在子宫内膜异位组织内,研究发现异位子宫内膜组织也可具有合成雌二醇的作用。以AIs为主的治疗方案目前已经广泛应用到子宫内膜异位症的治疗,对盆腔疼痛和不孕的患者具有一定临床疗效。本文旨在综述使用AIs治疗子宫内膜异位症相关疼痛和不孕的作用。
Endometriosis is an estrogen dependent gynecologic chronic inflammatory disease. The incidence in women of childbearing age is about 5% ~ 10%,of which 5% ~ 50% of the endometriosis patients show infertility,while 33% show manifestations of chronic pelvic pain. The third-generation aromatase inhibitors（ AIs） are currently approved for the treatment of estrogen receptor positive breast cancer. Molecular biology studies have shown that aromatase P450 is a key enzyme in the biosynthesis of ovarian estrogen in endometriosis tissues. It is also found that the ectopic endometrial tissue may also have the effect of oestradiol synthesis. AIs based treatment has been widely used in the treatment of endometriosis,pelvic pain and infertility in patients with a certain clinical efficacy. The purpose of this review is to investigate the role of AIs in the treatment of endometriosis associated pain and infertility.
出处
《中国性科学》
2018年第2期45-48,共4页
Chinese Journal of Human Sexuality
